Werewolf Therapeutics, Inc. (HOWL)

Over the past six months, Werewolf Therapeutics' stock price has been impacted by several significant events. In November 2025, the company reported its Q3 2025 earnings, received Fast Track Designation from the FDA for WTX-124, and notified Nasdaq of non-compliance with audit committee requirements. In December 2025, Wedbush downgraded Werewolf Therapeutics and cut its price target. In February 2026, Werewolf Therapeutics announced a significant workforce reduction and plans to explore strategic alternatives, also receiving a deficiency notice from Nasdaq. In March 2026, the company reported its Q4 and full-year 2025 financial results, with a narrowed net loss, and its stock price showed volatility.

Werewolf Therapeutics, Inc. does not currently have revenue-generating products on the market, so traditional product demand seasonality is not applicable to its operations or financial performance. The company's focus is on research, development, and clinical trials, which are not subject to seasonal fluctuations in demand.

Werewolf Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics that stimulate the body's immune system to treat cancer and other immune-mediated conditions. The company uses its PREDATOR® platform to design conditionally activated INDUKINE™ and INDUCER™ molecules that activate selectively in the tumor microenvironment. The company's major product candidates include WTX-124, WTX-330, JZP898, WTX-921, WTX-712, WTX-518, WTX-1011, and WTX-2022.

Werewolf Therapeutics, Inc. is headquartered in Watertown, Massachusetts, and was initially established in Cambridge, Massachusetts. The company's presence and operational focus are primarily within the United States, especially concerning its research, development, and regulatory activities with the FDA.

In the past year, Werewolf Therapeutics' reputation has been significantly affected by financial challenges and strategic uncertainties. Events such as the workforce reduction and the exploration of strategic alternatives have signaled operational challenges and increased investor uncertainty. The company also received a Nasdaq deficiency notice for not meeting the minimum bid price requirement. Consistent net losses and reliance on equity financing have contributed to negative investor sentiment.

Werewolf Therapeutics, Inc.'s ownership structure includes institutional, insider, and retail investors. As of March 26, 2026, the company has 57 institutional owners holding a total of 19,104,858 shares. Major institutional owners include Ra Capital Management, L.P., MPM Asset Management LLC, and Vanguard Group Inc. The largest individual shareholder is Ansbert Gadicke, owning 10.69 million shares, representing 22.02% of the company.